An exciting proof-of-concept study of Lutetium-177 PSMA (Lu PSMA) was published in the journal Lancet Oncology. Lu-PSMA has been described as “a disruptive therapy and has the potential to change practice” in the future treatment of men with end-stage prostate cancer.